Top-Rated StocksTop-RatedNASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis $21.11 +0.35 (+1.69%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Travere Therapeutics Stock (NASDAQ:TVTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Travere Therapeutics alerts:Sign Up Key Stats Today's Range$20.15▼$21.7150-Day Range$13.49▼$21.4052-Week Range$5.79▼$25.29Volume1.40 million shsAverage Volume1.52 million shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/APrice Target$31.79Consensus RatingModerate Buy Company OverviewTravere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More… Travere Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreTVTX MarketRank™: Travere Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 577th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTravere Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Travere Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($1.40) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 7.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.71% of the float of Travere Therapeutics has been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 4.41%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.71% of the float of Travere Therapeutics has been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 4.41%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News Sentiment1.05 News SentimentTravere Therapeutics has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Travere Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 2 people have searched for TVTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,507,377.00 in company stock.Percentage Held by InsidersOnly 4.06% of the stock of Travere Therapeutics is held by insiders.Read more about Travere Therapeutics' insider trading history. Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TVTX Stock News HeadlinesTravere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call TranscriptMay 2 at 12:11 AM | seekingalpha.comTravere Therapeutics, Inc. 2025 Q1 - Results - Earnings Call PresentationMay 1 at 11:08 PM | seekingalpha.comTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…May 2, 2025 | Crypto 101 Media (Ad)Travere Therapeutics Reports First Quarter 2025 Financial ResultsMay 1 at 4:01 PM | businesswire.comTravere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA NephropathyApril 29 at 10:46 AM | finance.yahoo.comCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA NephropathyApril 29 at 2:00 AM | prnewswire.comCantor Fitzgerald Reiterates Overweight Rating for Travere Therapeutics (NASDAQ:TVTX)April 25, 2025 | americanbankingnews.comTravere Therapeutics to Report First Quarter 2025 Financial ResultsApril 24, 2025 | finance.yahoo.comSee More Headlines TVTX Stock Analysis - Frequently Asked Questions How have TVTX shares performed this year? Travere Therapeutics' stock was trading at $17.42 at the start of the year. Since then, TVTX stock has increased by 17.7% and is now trading at $20.5030. View the best growth stocks for 2025 here. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its quarterly earnings results on Thursday, May, 1st. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.08. The firm's quarterly revenue was up 83.3% compared to the same quarter last year. Read the conference call transcript. Who are Travere Therapeutics' major shareholders? Travere Therapeutics' top institutional shareholders include Emerald Advisers LLC (2.34%), Emerald Mutual Fund Advisers Trust (1.26%), Assenagon Asset Management S.A. (0.47%) and Bank of New York Mellon Corp (0.26%). Insiders that own company stock include Eric M Dube, Steve Aselage, Peter Heerma, William E Rote, Christopher R Cline, Jula Inrig, Jeffrey A Meckler, Elizabeth E Reed, Sandra Calvin, Gary A Lyons, Laura Clague and Roy D Baynes. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Travere Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Home Depot (HD), Walmart (WMT), Netflix (NFLX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO). Company Calendar Last Earnings5/01/2025Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVTX CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees460Year FoundedN/APrice Target and Rating Average Stock Price Target$31.79 High Stock Price Target$47.00 Low Stock Price Target$20.00 Potential Upside/Downside+50.6%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($4.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,400,000.00 Net Margins-137.90% Pretax Margin-171.40% Return on Equity-1,636.87% Return on Assets-55.95% Debt Debt-to-Equity Ratio24.96 Current Ratio1.71 Quick Ratio1.68 Sales & Book Value Annual Sales$233.18 million Price / Sales8.04 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book7.91Miscellaneous Outstanding Shares88,772,000Free Float75,123,000Market Cap$1.87 billion OptionableOptionable Beta0.84 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:TVTX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.